It has shown its downregulated expression in other cancers like cervical cancer by directly targeting MAPK1, neuroblastoma tumor tissue, gastric cancer by directly targeting TIAM1, colorectal cancer by targeting TGF-β/Smad pathway, thyroid cancer by targeting WNT1, and pancreatic cancer by targeting grb2 [25-29]. This evidence concerns the gene MAPK1 and thyroid gland carcinoma.